Skip to main content
SpringerLink
Log in

Molecular imaging of glutamate-carboxypeptidase II (prostate-specific membrane antigen) in malignant epithelioid hemangioendothelioma

  • Image of the Month
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Cho SY, Gage KL, Mease RC, et al. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med. 2012;53:1883–91.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. J Nucl Med. 2015;56:668–74.

    Article  PubMed  Google Scholar 

  3. Afshar-Oromieh A, Haberkorn U, Schlemmer HP, et al. Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging. 2014;41:887–97.

    Article  CAS  PubMed  Google Scholar 

  4. Herrmann K, Bluemel C, Weineisen M, et al. Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy. J Nucl Med. 2015;56:855–61.

    Article  CAS  PubMed  Google Scholar 

  5. Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res. 1999;5:2674–81.

    CAS  PubMed  Google Scholar 

Download references

Compliance with Ethical Standards

Funding

none

Conflict of interest

Thorsten Derlin, Ulrich Baumann, and Frank M. Bengel each declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study or from their legal guardians.

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Hannover Medical School, Carl-Neuberg-Str. 1, D-30625, Hannover, Germany

    Thorsten Derlin & Frank M. Bengel

  2. Department of Paediatric Gastroenterology and Hepatology, Children´s Hospital, Hannover Medical School, Hannover, Germany

    Ulrich Baumann

Authors
  1. Thorsten Derlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ulrich Baumann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Frank M. Bengel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thorsten Derlin.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Derlin, T., Baumann, U. & Bengel, F.M. Molecular imaging of glutamate-carboxypeptidase II (prostate-specific membrane antigen) in malignant epithelioid hemangioendothelioma. Eur J Nucl Med Mol Imaging 42, 1943–1944 (2015). https://doi.org/10.1007/s00259-015-3161-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-015-3161-z

Keywords

Search

Navigation